research Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results
Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
Search
for
Sort by
Research
420-450 / 1000+ results 
research Development and Assessment of an Artificial Intelligence–Based Tool for Skin Condition Diagnosis by Primary Care Physicians and Nurse Practitioners in Teledermatology Practices
The AI tool helped primary care doctors and nurse practitioners diagnose skin conditions more accurately.
research The coudability sign of alopecia areata: the real story
The document concludes that anticonvulsants like phenytoin may cause skin reactions by affecting tryptophan metabolism and suggests researching vitamin levels in patients with drug reactions.
research My First Terrible Diagnosis
The medical student learned to balance medical knowledge with empathy when delivering difficult news to patients.
research Lights triggered differential accumulation of antioxidant and antidiabetic secondary metabolites in callus culture of Eclipta alba L.
Red light boosts beneficial compounds in Eclipta alba cultures.
research Unraveling the Complex: Changes in Secondary Science Preservice Teachers' Assessment Expertise
Changes in early neurosteroid levels can affect adult learning and anxiety.
research Effects of adenosine triphosphate on vandetanib induced skin damage in rats
ATP helps prevent skin damage from vandetanib by reducing stress.
research Diagnostic approach to the pruritic cat
Finding the cause of a cat's itchiness requires a careful process and good communication with the owner.
research Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials
Some patients on Baricitinib for alopecia areata lost response, often linked to longer and more severe initial conditions.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research 368 The Unanticipated Costs, Deficits, and Other Unexpected Burdens in a Diagnosis of Alopecia Areata
Alopecia areata requires addressing both emotional and financial challenges for better patient care.
research Analysis of clinical and histologic correlations in alopecia areata and telogen effluvium: adversities in alopecia pattern mimicry.
The study found that it's hard to tell the difference between two types of hair loss, alopecia areata and telogen effluvium, by looking at symptoms and tissue samples.
research Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
research Shaved hair style scalp medical tattooing technique for treatment of advanced male pattern baldness patients.
SMT effectively treats advanced baldness with high satisfaction.
research Kelayakan Hair Tonic Jahe Pada Jenis Rambut Rontok
Ginger hair tonic can reduce hair loss and improve hair quality.
research Bad medicine: misconceptions and misuses revealed, from distance healing to vitamin O
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research Finasteride-related self-harm and suicidal ideation
research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
research Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results
Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
research Blinding in Placebo-Controlled Trials
The conclusion is that maintaining blinding in clinical trials is crucial for reliable results.
research P56 Azathioprine-induced alopecia totalis and knuckle hyperpigmentation in a child with uveitis: test before you leap!
Monitor for early signs of azathioprine toxicity and check blood counts regularly.
research Suicidal ideation in patients undergoing treatment with 5α-reductase inhibitors
Patients with mood disorders using 5α-reductase inhibitors may have a higher risk of suicidal thoughts.
research Fronteggiare l’inaffidabilità della letteratura da studi clinici
Public health decisions should rely on independent trials, not biased literature.
research Barbers' education; a window to improve the public about skin diseases.
Educating barbers can help improve public awareness of skin diseases.
research Repurposing of H1-receptor antagonists (levo)cetirizine, (des)loratadine, and fexofenadine as a case study for systematic analysis of trials on clinicaltrials.gov using semi-automated processes with custom-coded software
Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
research Editorial Comment
5-ARI therapy may help prevent prostate cancer progression.
research Traction Alopecia
Stopping tight hairstyles can prevent and reduce traction alopecia.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.